Protecting your cells from harvest to administration27 May 2020
Phil Morton, Chief Technology Officer within Albumedix, recently digitally presented at the American Society for Gene & Cell Therapy (ASGCT) 2020 annual meeting.
Increasing performance of your cells from harvest to administration; addressing logistical challenges with an optimized cryopreservation solution
The presentation shares new data on the benefits on Albumedix recombinant human albumin (rAlb) products in the cryopreservation of induced pluripotent stem cells (iPSC's). Data showing significant increase in mesenchymal cell (MSC) viability post cryopreservation compared to HSA is also shared.
Phil shares insights on how to increase the performance of cells from harvest to administration, specifically addressing logistical challenges with an optimized cryopreservation solution.
*MSC data has been developed together with University of Barcelona and biotech company Xcelia.
*iPSC data has been developed with the international biomedical research institute Centre for Genomic Regulation in Barcelona